I
Ian Frank
Researcher at University of Pennsylvania
Publications - 183
Citations - 12190
Ian Frank is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Viral load & Vaccination. The author has an hindex of 51, co-authored 169 publications receiving 9909 citations.
Papers
More filters
Journal ArticleDOI
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
Pablo Tebas,David Stein,Winson Tang,Ian Frank,Shelley Wang,Gary Lee,S. Kaye Spratt,Richard T. Surosky,Martin Giedlin,Geoff Nichol,Michael C. Holmes,Philip D. Gregory,Dale G. Ando,Michael Kalos,Ronald G. Collman,Gwendolyn Binder-Scholl,Gabriela Plesa,Wei-Ting Hwang,Bruce L. Levine,Carl H. June +19 more
TL;DR: CCR5-modified autologous CD4 T-cell infusions are safe within the limits of this study, and HIV RNA became undetectable in one of four patients who could be evaluated.
Journal ArticleDOI
Topographical Continuity of Bacterial Populations in the Healthy Human Respiratory Tract
Emily S. Charlson,Kyle Bittinger,Andrew R. Haas,Ayannah S. Fitzgerald,Ian Frank,Anjana Yadav,Frederic D. Bushman,Ronald G. Collman +7 more
TL;DR: The healthy lung does not contain a consistent distinct microbiome, but instead contains low levels of bacterial sequences largely indistinguishable from upper respiratory flora, in contrast to other organ systems.
Journal ArticleDOI
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections
Jason M. Brenchley,Mirko Paiardini,Kenneth S. Knox,Kenneth S. Knox,Ava I. Asher,Barbara Cervasi,Tedi E. Asher,Phillip Scheinberg,David Price,David Price,Chadi A. Hage,Chadi A. Hage,Lisa M. Kholi,Alexander Khoruts,Ian Frank,James G. Else,Timothy W. Schacker,Guido Silvestri,Daniel C. Douek +18 more
TL;DR: Observations on Th17 cells in the blood, GI tract, and broncheoalveolar lavage of HIV-infected and uninfected humans, and SIV- infected and unin infected sooty mangabeys further elucidate the immunodeficiency of HIV disease and may provide a mechanistic basis for the mucosal barrier breakdown that characterizes HIV infection.
Journal ArticleDOI
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer,Magdalena E. Sobieszczyk,Holly Janes,Shelly Karuna,Mark J. Mulligan,Doug Grove,Beryl A. Koblin,Susan Buchbinder,Michael C. Keefer,Georgia D. Tomaras,Nicole Frahm,John Hural,Chuka Anude,Barney S. Graham,Mary E. Enama,Elizabeth Adams,Edwin DeJesus,Richard M. Novak,Ian Frank,Carter Bentley,Shelly Ramirez,Rong Fu,Richard A. Koup,John R. Mascola,Gary J. Nabel,David C. Montefiori,James G. Kublin,M. Juliana McElrath,Lawrence Corey,Peter B. Gilbert +29 more
TL;DR: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied and had an acceptable side-effect profile.
Journal ArticleDOI
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
Rishi R. Goel,Mark M Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M Drapeau,Jeanette Dougherty,Sherea Long,Kurt D'Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,S. Adamski,Z. Alam,M. M. Addison,K. T. Byrne,A. Chandra,H. C. Descamps,Nicholas Han,Y. Kaminskiy,S. C. Kammerman,Justin Kim,A. R. Greenplate,J. T. Hamilton,N. Markosyan,J. Han Noll,D. K. Omran,A. Pattekar,E. Perkey,E. M. Prager,D. Pueschl,A. Rennels,J. B. Shah,J. S. Shilan,N. Wilhausen,A. N. Vanderbeck +70 more
TL;DR: The durability of immune memory after SARS-CoV-2 mRNA vaccination was investigated in this article, where the majority of these cells cross-binding the Alpha, Beta, and Delta variants.